SCHEMBL2669451

SCHEMBL2669451

C=C/C=C\C=N/N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4069944 0.74
SCHEMBL316478 0.68
SCHEMBL130885 0.68
SCHEMBL851233 0.68
SCHEMBL24717370 0.67
SCHEMBL28188408 0.67
SCHEMBL7992428 0.67
SCHEMBL10066350 0.67
SCHEMBL23810239 0.67
SCHEMBL12328713 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230337520-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-10-19 US disclosed
US-11214544-B2 Dextrorphan prodrugs and processes for making and using them KEMPHARM, INC. (US) 2022-01-04 US disclosed
US-20200392087-A1 DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM ALTER DOMUS (US) LLC 2020-12-17 US disclosed
WO-2020116296-A1 FLUORINATED PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR ユニマテック株式会社 2020-06-11 WO disclosed
WO-2017012647-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS GALAPAGOS NV (BE) 2017-01-26 WO disclosed
US-20170007611-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS, INC. 2017-01-12 US disclosed
US-20160324859-A1 USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK) PHARMACYCLICS, INC. 2016-11-10 US disclosed
US-20160303130-A1 METHODS FOR TREATING B CELL PROLIFERATIVE DISORDERS CORNELL UNIVERSITY 2016-10-20 US disclosed
US-20160243033-A1 METHODS OF TREATING ABC-DLBCL USING INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2016-08-25 US disclosed
US-9421208-B2 Methods for the treatment of solid tumors PHARMACYCLICS LLC (US) 2016-08-23 US disclosed
US-7906553-B2 Substituted thiophene modulators of intracellular calcium CALCIMEDICA, INC. (US) 2011-03-15 US disclosed
EP-1756104-B1 TETRAHYDRONAPHTHYRIDINE DERIVATIVES USEFUL AS HISTAMINE H3 RECEPTOR LIGANDS PFIZER LTD (GB) 2010-12-15 EP disclosed
US-20100261725-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2010-10-14 US disclosed
WO-2010088524-A2 CONVERSION OF CARBON DIOXIDE TO ORGANIC PRODUCTS PRINCETON UNIVERSITY (US) 2010-08-05 WO disclosed
WO-2009134392-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009134384-A1 CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 VITAE PHARMACEUTICALS, INC. (US) 2009-11-05 WO disclosed
WO-2009047798-A2 ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATIONS ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) 2009-04-16 WO disclosed
WO-2008055959-A1 NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE &amp; INFLAMMATORY DISEASES GALAPAGOS N.V. (BE) 2008-05-15 WO disclosed
WO-2008030617-A2 CANCER THERAPY WITH CANTHARIDIN AND CANTHARIDIN ANALOGS STEMLINE THERAPEUTICS, INC. (US) 2008-03-13 WO disclosed
WO-2005016272-A2 ARYL, HETEROAROMATIC AND BICYCLIC ARYL NITRONE COMPOUNDS, PRODRUGS AND PHARMACEUTICAL COMPOSITIONS OF THE SAME TO TREAT HUMAN DISORDERS RENOVIS, INC. (US) 2005-02-24 WO disclosed